Physician profile
William E Parrish
NPI 1609880707
$4,554.57
in general payments reported to CMS, 2019-2025
29 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,578 · 2020: $200 · 2021: $14.82 · 2023: $147 · 2024: $454 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $661.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $618.67 | 2019-2025 | |
| Amgen INC. | $297.08 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $279.05 | 2019-2020 | |
| Lilly USA, LLC | $248.83 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $239.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $232.26 | 2019-2020 | |
| Glaxosmithkline, LLC. | $231.39 | 2019 | |
| Supernus Pharmaceuticals, INC. | $216.38 | 2019 | |
| Upsher-Smith Laboratories LLC | $184.38 | 2019-2020 | |
| Amarin Pharma, INC. | $181.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.06 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $144.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.31 | 2019 | |
| Phathom Pharmaceuticals, INC. | $126.74 | 2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $101.52 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $61.52 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.34 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $54.67 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $46.53 | 2025 | |
| Smith+Nephew, INC. | $45.36 | 2019-2021 | |
| Mannkind Corporation | $44.02 | 2019 | |
| Merck Sharp & Dohme LLC | $38.65 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $28.77 | 2019 | |
| Axsome Therapeutics, INC. | $24.77 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $24.02 | 2019 | |
| Abbott Laboratories | $17.66 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $13.31 | 2019 | |
| Shire North American Group INC | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.